DeepMed Research

Nanfang Hospital Southern Medical University

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Carelizumab Combined With Regorafenib in the Treatment of HCC（CARE-2020）

Phase 2

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Regorafenib Pill&Camrelizumab

First Posted Date: 2021-03-19

Last Posted Date: 2021-06-30

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 69

Registration Number: NCT04806243

Locations: 🇨🇳
NanFang Hospital of Southern Medical University, Guangzhou, Guangdong, China

Effect of Antiviral Therapy on HVPG in Patients With Viral Cirrhosis

Conditions: Portal Hypertension

First Posted Date: 2021-03-15

Last Posted Date: 2021-03-15

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 24

Registration Number: NCT04797910

The Role of HSP90 in Peripheral Vascular Lesions of Diabetic Atherosclerosis

Completed

Conditions: Peripheral Arterial Disease

Interventions: Other: non-intervention

First Posted Date: 2021-03-09

Last Posted Date: 2021-03-09

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 150

Registration Number: NCT04787770

Locations: 🇨🇳
Nanfang Hospital, Guangzhou, Guangdong, China

Influence of Co-existing Mutations on Sorafenib Maintenance Therapy After Allo-HSCT for Patients With FLT3-ITD AML

Completed

Conditions: Acute Myeloid Leukemia With FLT3/ITD Mutation
Hematopoietic Stem Cell Transplantation
Acute Myeloid Leukemia

Interventions: Drug: Sorafenib

First Posted Date: 2021-03-09

Last Posted Date: 2022-06-01

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 456

Registration Number: NCT04788420

Locations: 🇨🇳
Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

Thromboelastography Guides a Multicentre Cluster Controlled Study of Plasma Exchange for Hepatitis B Associated Acute-on-chronic Liver Failure

Not Applicable

Conditions: 28 Day Mortality

Interventions: Biological: plasma exchange

First Posted Date: 2021-02-10

Last Posted Date: 2021-02-10

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 390

Registration Number: NCT04747106

Locations: 🇨🇳
Nanfang Hospital, Guangzhou, Guangdong, China

Induced-T Cell Like NK Cells for B Cell Malignancies

Phase 1

Conditions: B Cell Leukemia
B Cell Lymphoma
B-cell Acute Lymphoblastic Leukemia
B-cell Lymphoma Refractory
B-cell Lymphoma Recurrent

Interventions: Biological: CAR-ITNK cells

First Posted Date: 2021-02-10

Last Posted Date: 2021-02-10

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 12

Registration Number: NCT04747093

Locations: 🇨🇳
Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

Neoadjuvant Immunotherapy and Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial

Phase 2

Recruiting

Conditions: Gastric Cancer
Stomach Neoplasm

Interventions: Drug: XELOX or SOX
Drug: JS001+XELOX or SOX

First Posted Date: 2021-02-09

Last Posted Date: 2022-11-15

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 110

Registration Number: NCT04744649

Locations: 🇨🇳
The six affiliated hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
🇨🇳
Mao ming people's hospital, Maoming, Guangdong, China
🇨🇳
The Eighth Affiliated Hospital, Sun Yat-Sen University, Shenzhen, Guangdong, China

and more 7 locations

Population Pharmacokinetics of Tigecycline in Patients Treated With ECMO

Conditions: Tigecycline
Pharmacokinetics
Extracorporeal Membrane Oxygenation

First Posted Date: 2021-01-26

Last Posted Date: 2021-01-26

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 10

Registration Number: NCT04724798

Locations: 🇨🇳
Southern medical university Nanfang hospital, Guangzhou, China

G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for RAEB-1,REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT

Phase 2

Conditions: Conditioning
Myelodysplastic Syndrome
Allogeneic Hematopoietic Stem Cell Transplantation

Interventions: Drug: Granulocyte Colony-Stimulating Factor(G-CSF)
Drug: Decitabine (DAC)
Drug: Busulfan (BU)
Drug: Cyclophosphamide (CY)
Drug: Fludarabine (FLU)

First Posted Date: 2021-01-19

Last Posted Date: 2021-01-19

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 242

Registration Number: NCT04713956

Locations: 🇨🇳
Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

Whole-genome Sequencing Study in Patients With Diminished Ovarian Reserve

Conditions: Diminished Ovarian Reserve

Interventions: Other: whole-genome sequencing

First Posted Date: 2021-01-15

Last Posted Date: 2021-01-15

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 140

Registration Number: NCT04711772

Locations: 🇨🇳
Center for Reproductive Medicine, Department of Gynecology and Obstetrics, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy